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Notch signaling regulates many aspects of metazoan development and tissue renewal. Accord-
ingly, the misregulation or loss of Notch signaling underlies a wide range of human disorders, 
from developmental syndromes to adult-onset diseases and cancer. Notch signaling is remarkably 
robust in most tissues even though each Notch molecule is irreversibly activated by proteolysis 
and signals only once without amplification by secondary messenger cascades. In this Review, we 
highlight recent studies in Notch signaling that reveal new molecular details about the regulation 
of ligand-mediated receptor activation, receptor proteolysis, and target selection.Diversity among different species and cell types appears to 
have evolved through the combinatorial use of a relatively 
small number of conserved signaling pathways. Among these, 
the Notch signaling pathway of metazoans enables short-
range communication between cells. Indeed, transmission of 
Notch signals requires physical contact between cells under 
most circumstances. Notch signals are often used to select 
between preexisting developmental programs. In a context-
dependent manner, Notch signals can promote or suppress 
cell proliferation, cell death, acquisition of specific cell fates, 
or activation of differentiation programs. This occurs in cells 
throughout development of the organism and during the 
maintenance of self-renewing adult tissues. Because Notch 
plays a critical role in many fundamental processes and in a 
wide range of tissues, it is not surprising that aberrant gain or 
loss of Notch signaling components has been directly linked 
to multiple human disorders. These disorders include devel-
opmental syndromes (for example, Alagille syndrome, Tetral-
ogy of Fallot, syndactyly, spondylocostal dysostosis, familial 
aortic valve disease; Garg et al., 2005; Gridley, 2003), adult-
onset diseases (such as CADASIL, cerebral autosomal domi-
nant arteriopathy with subcortical infarcts and leukoenceph-
alopathy; Louvi et al., 2006), and cancer. Notch signaling has 
emerged as a specific therapeutic target for T cell acute lym-
phoblastic leukemia (Weng et al., 2004) and colon cancer (van 
Es et al., 2005), as well as a potential target in the effort to 
curb tumor angiogenesis (Noguera-Troise et al., 2006; Ridg-
way et al., 2006). In addition to its importance in disease, any 
meaningful manipulation of embryonic or adult stem cells will 
also require the development of receptor-specific antagonists 
and agonists of Notch signaling. As a consequence, research 
that examines the finer mechanistic details of Notch activa-
tion and nuclear activity is of growing clinical and commercial 
relevance.
A hallmark of Notch signaling that sets it apart from other 
conserved signaling pathways is its mechanism of signal 
transduction. Notch signaling relies on the ability of a ligand 
to bring about receptor proteolysis, resulting in the release 216 Cell 137, April 17, 2009 ©2009 Elsevier Inc.of an active Notch fragment. A second unusual feature of 
Notch signaling is that intramembrane proteolysis is involved 
in receptor activation. After its release by proteolysis from a 
membrane tether, the Notch intracellular domain (NICD) trav-
els to the nucleus. There, the NICD associates with a DNA 
binding protein to assemble a transcription complex that acti-
vates downstream target genes (Figure 1). This core signal 
transduction pathway is used in most Notch-dependent pro-
cesses and is known as the “canonical” pathway. However, 
depending on the cellular context, the amplitude and duration 
of Notch activity can be further regulated at various points 
in the pathway. Here, we summarize our current understand-
ing of canonical Notch signaling mechanisms and highlight 
recent studies that bring new insights into the molecular and 
biochemical events that occur during ligand-receptor recog-
nition, receptor activation, intramembrane proteolysis, and 
target gene selection.
A Growing Roster of Core Pathway Components
Notch receptors are large single-pass type I transmembrane 
proteins (see Figure 2A for domain organization). Whereas 
the fly Drosophila melanogaster possesses only one Notch 
receptor and the worm Caenorhabditis elegans possesses 
two redundant Notch receptors, mammals have four Notch 
paralogs that display both redundant and unique functions 
(Table 1). The extracellular domain of all Notch proteins 
contains 29–36 tandem epidermal growth factor (EGF)-like 
repeats, some of which mediate interactions with the Notch 
ligand (Figure 2A). Productive interactions with ligands pre-
sented by neighboring cells (trans interactions) require repeats 
11–12. In contrast, cis-inhibition by ligands expressed in the 
same cell depend on an activity that maps to the Abruptex 
region of Drosophila Notch, which includes EGF repeats 
24–29. Many EGF repeats bind to calcium ions, which play 
an important role in determining the structure and affinity of 
Notch in ligand binding (Cordle et al., 2008b) and can affect 
signaling efficiency (Raya et al., 2004). Within the extracel-
lular domain structure, the EGF repeats are followed by a 
unique negative regulatory region (NRR), which is composed 
of three cysteine-rich Lin12-Notch repeats (LNR) and a het-
erodimerization domain (Figure 2A). The negative regulatory 
region plays a critical role in preventing receptor activation in 
the absence of ligands and will be discussed in detail later. 
Most surface Notch proteins are cleaved by furin-like con-
vertases within the secretory pathway (Figure 1) at site 1 (S1) 
located within an unstructured loop that protrudes from the 
heterodimerization domain. This cleavage event converts the 
Notch polypeptide into an NECD-NTMIC (Notch extracellular 
domain-Notch transmembrane and intracellular domain) het-
erodimer held together by noncovalent interactions between 
the N- and C-terminal halves of the heterodimerization domain 
(Figures 1 and 2A).
The single transmembrane domain of the Notch receptor 
ends with a C-terminal “stop translocation” signal comprised 
of 3–4 arginine/lysine (Arg/Lys) residues. Intracellularly, the 
RAM (RBPjκ association module) domain forms a high-
affinity binding module of 12–20 amino acids centered on a 
conserved WxP (tryptophan-any amino acid-proline) motif. 
A long, unstructured linker containing a nuclear localization 
sequence links the RAM domain to seven ankyrin repeats 
(ANK domain). Following the ANK domain is an additional 
bipartite nuclear localization sequence and a loosely defined 
and evolutionarily divergent transactivation domain. The very 
C terminus of the receptor contains conserved proline/glu-
tamic acid/serine/threonine-rich motifs (PEST) that harbor 
degradation signals (degrons), which regulate the stability of 
NICD. Drosophila Notch also contains a glutamine-rich repeat 
(OPA) (Figure 2A).
Our understanding of Notch ligands is rapidly evolving. Most 
Notch ligands are themselves type I transmembrane proteins 
(Figure 2B) (reviewed in D’Souza et al., 2008). Recent studies 
have refined our understanding of their structure and func-
tion (Cordle et al., 2008a; Komatsu et al., 2008). The largest 
class of Notch ligands is characterized by three related struc-
tural motifs: an N-terminal DSL (Delta/Serrate/LAG-2) motif, 
specialized tandem EGF repeats called the DOS (Delta and 
OSM-11-like proteins) domain (Komatsu et al., 2008), and EGF-
like repeats (both calcium binding and non-calcium binding) 
(Figure 2B). DSL ligands can be classified on the basis of the 
presence or absence of a cysteine-rich domain (Jagged/Ser-
rate or Delta, respectively) and the presence or absence of a 
DOS domain (Figure 2B). As we will detail later, both the DSL 
and DOS domains are involved in receptor binding. Additional 
proteins lacking DSL and DOS domains have been reported to 
act as noncanonical ligands for Notch receptors in the central 
nervous system and in cultured cells (for example, F3/Contac-
tin1, NB-3/Contactin6, DNER, MAGP1, and MAGP2) (Figure 
2B, Table 1) (reviewed in D’Souza et al., 2008). However, these 
activities have been largely unexplored, and the physiological 
functions for these proteins in the Notch pathway remain to be 
elucidated.
It is now well established that Notch receptor activation 
is mediated by a sequence of proteolytic events (Figures 1 
and 2A) (reviewed in Bray, 2006). Ligand binding leads to 
the cleavage of Notch by ADAM (a disintegrin and metal-
loprotease) proteases at site 2 (S2), located ?12 amino acids before the transmembrane domain and deeply bur-
ied within the negative regulatory region (Figures 2 and 3A). 
Site 2 cleavage is a key regulatory step in Notch activa-
tion, but some ambiguity still exists regarding the enzymes 
that mediate cleavage. Indeed, only ADAM17/TACE (tumor 
Figure 1. The Core Notch Signaling Pathway Is Mediated by 
 Regulated Proteolysis
The newly translated Notch receptor protein is glycosylated by the enzymes O-
fut and Rumi, which are essential for the production of a fully functional recep-
tor. The mature receptor is produced after proteolytic cleavage by PC5/furin at 
site 1 (S1). It is then targeted to the cell surface as a heterodimer that is held to-
gether by noncovalent interactions. In cells expressing the glycosyltransferase 
Fringe, the O-fucose is extended by Fringe enzymatic activity, thereby altering 
the ability of specific ligands to activate Notch. The Notch receptor is activated 
by binding to a ligand presented by a neighboring cell. Endocytosis and mem-
brane trafficking regulate ligand and receptor availability at the cell surface. 
Ligand endocytosis is also thought to generate mechanical force to promote 
a conformational change in the bound Notch receptor. This conformational 
change exposes site 2 (S2) in Notch for cleavage by ADAM metalloproteases 
(perhaps after heterodimer dissociation at site 1). Juxtamembrane Notch cleav-
age at site 2 generates the membrane-anchored Notch extracellular truncation 
(NEXT) fragment, a substrate for the γ-secretase complex. γ-Secretase then 
cleaves the Notch transmembrane domain in NEXT progressively from site 
3 (S3) to site 4 (S4) to release the Notch intracellular domain (NICD) and Nβ 
peptide. γ-Secretase cleavage can occur at the cell surface or in endosomal 
compartments, but cleavage at the membrane favors the production of a more 
stable form of NICD. NICD then enters the nucleus where it associates with the 
DNA-binding protein CSL (CBF1/RBPjκ/Su(H)/Lag-1). In the absence of NICD, 
CSL may associate with ubiquitous corepressor (Co-R) proteins and histone 
deacetylases (HDACs) to repress transcription of some target genes. Upon 
NICD binding, allosteric changes may occur in CSL that facilitate displacement 
of transcriptional repressors. The transcriptional coactivator Mastermind (MAM) 
then recognizes the NICD/CSL interface, and this triprotein complex recruits 
additional coactivators (Co-A) to activate transcription.Cell 137, April 17, 2009 ©2009 Elsevier Inc. 217
Figure 2. Domain Organization of Notch Pathway Receptors, Ligands, and Coligands
(A) Notch receptors are large type I proteins that contain multiple extracellular EGF-like repeats. Drosophila Notch (dNotch) and the four mammalian Notch 
paralogs (mNotch1–4) differ in the number of repeats (29–36) but all are much longer than the C. elegans Notch proteins (cLIN-12 and cGLP-1). EGF repeats 
11–12 (red) and 24–29 (green) mediate ligand interactions. EGF repeats may contain consensus motifs for fucosylation by O-Fut1 and glucosylation by Rumi; 
the putative distribution of fucosylation sites (common, green; unique, light blue) and glucosylation sites (common, dark blue; unique, magenta) are shown for 
mNotch1 and mNotch2. Note that the ligand-binding regions differ in their modification patterns. EGF repeats are followed by the negative regulatory region 
(NRR), which is composed of three cysteine-rich Lin12-Notch repeats (LNR-A, -B, and -C) and a heterodimerization domain (HD). Notch also contains a trans-
membrane domain (TMD), a RAM (RBPjκ association module) domain, nuclear localization sequences (NLSs), a seven ankyrin repeats (ANK) domain, and a 
transactivation domain (TAD) that habors conserved proline/glutamic acid/serine/threonine-rich motifs (PEST). The transactivation domain in Drosophila Notch 
also has a glutamine-rich repeat (OPA). In contrast to Drosophila Notch, mammalian Notch proteins are cleaved by furin-like convertases at site 1 (S1), which 
converts the Notch polypeptide into an NECD-NTMIC (Notch extracellular domain-Notch transmembrane and intracellular domain) heterodimer that is held 
together by noncovalent interactions between the N- and C-terminal halves of the heterodimerization domain. (Inset) Details of the mouse Notch1 transmem-
brane domain (TMD) (purple box) and flanking residues showing the Notch cleavage sites and corresponding cleavage products. After ligand binding, Notch is 
cleaved at site 2 by metalloproteases. γ-Secretase can cleave multiple scissile bonds at site 3 (arrows), but only NICD molecules initiating at valine 1744 (V1744) 
(NICD-V) evade N-end rule degradation. Cleavage then proceeds toward site 4 until the short Nß peptides (most are 21 amino acids) can escape the membrane 
lipid bilayer. Amino acid substitution of V1744 to glycine (V1744G, red) and lysine 1749 to arginine (K1749R, blue) shift the cleavage site.
(B) Known ligands and putative ligands of Notch receptors can be divided into several groups on the basis of their domain composition. Classical DSL ligands 
(DSL/DOS/EGF ligands) contain the DSL (Delta/Serrate/LAG-2), DOS (Delta and OSM-11-like proteins), and EGF (epidermal growth factor) motifs and are not 
found in C. elegans. C. elegans and mammalian DSL-only ligands lacking the DOS motif (DSL/EGF ligands) are a subtype of DSL ligands that may act alone (for 
example, mDLL4) or in combination with DOS coligands (for example, cDSL-1 and possibly Dll3). This subfamily includes soluble/diffusible ligands. Noncanoni-
cal ligands lacking DSL and DOS domains have been reported to activate Notch in some contexts.necrosis factor α converting enzyme) is able to cleave Notch 
substrates in vitro, and yet TACE null mice do not have as 
severe a phenotype as Notch null mice. In contrast, the 
Kuzbanian/ADAM10/Sup-17 metalloprotease is essential for 
Notch activity in all phyla (Deuss et al., 2008).218 Cell 137, April 17, 2009 ©2009 Elsevier Inc.The shedding of the Notch ectodomain creates a mem-
brane-tethered intermediate called Notch extracellular trun-
cation (NEXT) that is a substrate for γ-secretase, a multi-
component member of a growing family of intramembrane 
cleaving proteases (I-CLiPs) (reviewed in Selkoe and Wolfe, 
Table 1. Core Components and Modifiers of the Notch Pathway
Component Function Type Drosophila Caenorhabditis elegans Mammals
Receptor Notch LIN-12, GLP-1 Notch 1–4
Ligand DSL/DOS Delta, Serrate Dll1, Jagged1 and 2
DSL only APX-1, LAG-2, ARG-2, 
DSL1–7
Dll3 and 4
DOS Coligands DOS1–3, OSM7 and 11 DLK-1, DLK-2/EGFL9
Noncanonical DNER, MAGP-1 and -2, F3/
Contactin1, NB-3/Contactin6
Nuclear Effectors CSL DNA-binding transcription
factor
Su(H) LAG-1 RBPjκ/CBF-1
Transcriptional Coactivator Mastermind LAG-3 MAML1-3
Transcriptional Corepressors Hairless, SMRTR Mint/Sharp/SPEN, NCoR/
SMRT, KyoT2
Receptor Proteolysis Furin convertase (site 1 cleavage) ? ? PC5/6, Furin
Metalloprotease (site 2 cleavage) Kuzbanian, 
 Kuzbanian-like, TACE
SUP-17/Kuzbanian, 
ADM-4/TACE
ADAM10/Kuzbanian, 
ADAM17/TACE
γ-secretase (site 3/site 4 cleavage) Presenilin, Nicastrin, 
APH-1, PEN-2
SEL-12, APH-1, APH-2, 
PEN-2
Presenilin 1 and 2, Nicastrin, 
APH-1a-c, PEN-2
Glycosyltransferase 
modifiers
O-fucosyl-transferase OFUT-1 OFUT-1 POFUT-1
O-glucosyl-transferase RUMI
β1,3-GlcNAc-transferase Fringe Lunatic, Manic, and Radical 
Fringe
Endosomal Sorting/
Membrane Trafficking 
Regulators
Ring Finger E3 Ubiquitin ligase (ligand 
endocytosis)
Mindbomb 1–2, 
 Neuralized
Mindbomb, Skeletrophin, 
Neuralized 1–2
Ring Finger E3 Ubiquitin ligase 
( receptor endocytosis)
Deltex Deltex 1–4
HECT Domain E3 Ubiquitin ligase 
(receptor endocytosis)
Nedd4, Su(Dx) WWP-1 Nedd4, Itch/AIP4
Negative regulator Numb Numb, Numb-like, ACBD3
Neuralized Inhibitors Bearded, Tom, M4
Other endocytic modifiers sanpodo
NICD Degradation F-Box Ubiquitin ligase Archipelago SEL-10 Fbw-7/SEL-10
Canonical Target bHLH 
Repressor Genes
E(spl) REF-1 HES/ESR/HEY
The Notch family of receptors mediates short-range communication between cells throughout development and during adult tissue renewal. During 
maturation and trafficking to the cell surface, Notch receptors undergo furin processing and glycosylation, which can impact their responsiveness to 
their ligands. The activity and availability of Notch receptors and ligands are also regulated by endocytic trafficking, which can be modulated by the 
activity of different ubiquitin ligases. A wide range of Notch ligands can bind and activate the Notch receptor, inducing further proteolytic processing 
of the receptor by specific proteases. The Notch intracellular domain (NICD), the end product of Notch receptor activation, localizes to the nucleus, 
where it associates with the DNA binding protein CSL [CBF1/RBPjk/Su(H)/Lag-1] and other transcriptional coactivators to bind and activate target 
genes. In the absence of NICD, CSL can also function in conjunction with transcriptional corepressor proteins to repress gene expression. DSL, 
Delta/Serrate/LAG-2 motif; DOS, Delta and OSM-11-like proteins motif.2007; Wolfe and Kopan, 2004). γ-Secretase cleaves NEXT 
progressively within the transmembrane domain, most likely 
starting near the inner plasma membrane leaflet at site 3 (S3) 
and ending near the middle of the transmembrane domain at 
site 4 (S4) (Figure 2A). Only after γ-secretase cleavage is the 
NICD free to translocate to the nucleus. There, NICD interacts 
with the DNA-binding protein CSL [CBF1/RBPjκ/Su(H)/Lag-1] 
first through its RAM domain. The ANK domain of NICD then 
associates with CSL to help recruit the coactivator Master-
mind/Lag-3, which in turn recruits the MED8 mediator tran-
scription activation complex, thereby inducing upregulation 
of downstream target genes (reviewed in Kovall, 2008) (Fig-ure 1). Additional proteins can also modify the output from 
Notch receptors (listed in Table 1 and presented in Ilagan and 
Kopan, 2007).
Regulation of Ligand-Receptor Interactions
Given that each Notch molecule undergoes proteolysis to 
generate a signal and thus can only signal once, regulation of 
either ligand or receptor availability at the cell surface is key 
to controlling Notch activation. One simple way of regulating 
availability is to restrict ligand or receptor expression spatially 
and temporally. Indeed, different ligands and receptors can 
have overlapping as well as distinct expression patterns dur-Cell 137, April 17, 2009 ©2009 Elsevier Inc. 219
ing development and are subject to regulation by other sig-
naling pathways (reviewed in Wu and Bresnick, 2007). Though 
important, differential expression patterns of the ligands and 
receptors are not enough to explain the observed differences 
in signaling activity. The regulation of trafficking and post-
translational modifications have emerged as important mecha-
nisms that control ligand or receptor availability and productive 
ligand-receptor interactions.
Ligand and Receptor Endocytosis and Trafficking
Endocytic trafficking of the DSL ligands plays a critical role in 
enhancing their signaling activity. This has been a subject of 
many excellent recent reviews (Le Borgne, 2006; Nichols et 
al., 2007b). Therefore, we will only summarize a few pertinent 
points here and discuss other aspects of endocytosis that are 220 Cell 137, April 17, 2009 ©2009 Elsevier Inc.more directly related to the receptor activation process later in 
the review. Ligand endocytosis is triggered by monoubiquitina-
tion that is mediated by the E3 ubiquitin ligases Neuralized and 
Mindbomb. After endocytosis, a poorly characterized process 
occurs to produce a more active cell surface ligand. Current 
models for the nature of ligand modification include clustering 
of the ligand, posttranslational modifications to the ligand, and 
recycling of the ligand into specific membrane microdomains 
(Le Borgne, 2006; Nichols et al., 2007b). Interestingly, bearded 
protein family members, which negatively regulate Neuralized 
activity and thus reduce the efficiency of Notch activation by 
Delta (Bardin and Schweisguth, 2006), are themselves Notch 
target genes (Lai et al., 2000). This regulation of Bearded pro-
teins by Notch constitutes a negative feedback loop that is 
Figure 3. Atomic Resolution of Domains in Human Notch1, Notch2, 
and Jagged1
(A) (Top) The ligand-binding domain (EGF 11–13) from the crystal structure 
of human Notch1 (PDB:2VJ3). The ligand-binding domain of Notch1 is cen-
tered on EGF repeat 12, which contains residues that coordinate Ca2+ binding 
(blue), as well as O-glucosylation (serine 458, serine 496) and O-fucosylation 
(threonine 466) sites. Mutation of glutamic acid 455 to valine (E455V) abol-
ishes ligand binding in Drosophila. This region in human Notch1 (hNotch1) 
was suggested to interact with human Jagged1 (hJagged1) DSL ligand on 
the basis of computational docking models (Cordle et al., 2008a). However, 
glycosylation at serine 458 may block access to this site. Threonine 466 is es-
sential for productive Notch activation in the mouse but not in the fly. (Bottom) 
The negative regulatory region from the crystal structure of human Notch2 
(PDB:2OO4). The negative regulatory region folds to protect the S2 cleavage 
site (green), which is located in a pocket protected by LNR-A, the HD-C helix, 
and the LNR-A/B linker. The furin cleavage site (S1) lies within an unstructured 
loop that was removed to facilitate crystallization. LNR repeats bind to cal-
cium ions; chelation of Ca2+ leads to negative regulatory region dissociation 
and Notch activation.
(B) The crystal structure of the hJagged1 Notch-binding domain (PDB:2VJ2) 
containing the DSL, DOS, and EGF repeat 3 (EGF-3) regions. (Left) The hJag-
ged1 ribbon structure.The DSL fold is distinct from the EGF fold; DSL amino 
acids required for interaction with Notch are labeled in red (Cordle et al., 
2008a). The phenylalanine 207 to alanine (F207A) substitution generates a null 
protein. In contrast, arginine 203 to alanine (R203A) and phenylalanine 199 to 
alanine (F199A) substitutions ablate binding of ligand presented from another 
cell (trans) but not cis binding of ligand present in the same cell. Aspartic acid 
205 to alanine (D205A) and arginine 201 to alanine (R201A) substitutions are 
hypomorphic. The DOS domain contains two conserved atypical EGF repeats 
(defined by the presence of the conserved amino acids in blue) (Komatsu et 
al., 2008). Tyrosine 255 (Y255) is characteristic of Jagged DSL ligands and is 
replaced by a small hydrophobic amino acid in Delta-like ligands (this residue 
may be involved in defining sensitivity to Fringe glycosyltransferase activity). 
(Right) Surface rendering of the hJagged1 ribbon structure. The structure is 
rotated so that the Notch-binding interface (dotted circles) is facing the read-
er. Surface exposed residues are indicated by white circles, whereas buried 
residues are indicated by green circles. Mapping of known Jagged mutations 
in humans and mouse to the structure indicates that the DOS domain could 
form part of the Notch-binding interface. Human Alagille syndrome (ALGS)-
associated missense mutations (orange) are likely to affect disulfide bonds 
(and thus the structural integrity of these domains). A positively charged clus-
ter of highly conserved surface-exposed residues within the DSL domain (red) 
identifies a putative Notch-binding surface. Interestingly, missense mutations 
(blue) associated with Tetralogy of Fallot in humans and autosomal dominant 
inner ear malformations in mice (headturner, slalom, and Nodder) cluster near 
a common DOS region. Mutations in headturner and Tetralogy of Fallot affect 
amino acids buried under the surface defined by slalom and Nodder muta-
tions and may impact the structure of the potential Notch binding site within 
DOS. Note that arginine 252 (mutated to lysine in ALGS1) and tyrosine 255 
(Y255), which is unique to Jagged, are also aligned with the putative Notch 
binding surfaces on the DSL and DOS domains. The exact topology of the 
Notch/ligand interface remains to be explored by cocrystallization. Structures 
were generated with MacPymol (http://www.pymol.org).
further fine-tuned by miRNAs that target bearded and E(spl) 
mRNAs (Lai et al., 2005; Stark et al., 2003), reducing their half 
life and mitigating their impact on Neuralized. In addition to 
regulating this aspect of endocytosis, miRNAs can also regu-
late Delta expression (Kwon et al., 2005).
As with the DSL ligands, several mechanisms control the 
steady-state levels of the Notch receptors at the cell surface 
and therefore regulate their availability for ligand binding. For 
example, several E3 ubiquitin ligases—Deltex, Nedd4, Su(Dx)/
Itch, Cbl—can direct Notch receptor trafficking toward lyso-
somal degradation or toward recycling, thereby impacting 
receptor half life (reviewed in Bray, 2006; Le Borgne, 2006; 
Nichols et al., 2007b). Numb, in cooperation with the AP2 com-
ponent α-adaptin and the AP2- or Numb-associated kinase 
(NAK), may promote Notch degradation in daughters of an 
asymmetrically dividing cell. In the majority of systems, Numb 
acts as a Notch antagonist, although in at least one context, 
Numb can act synergistically with Notch (Range et al., 2008). 
Numb is not active when lateral Notch signaling occurs between 
resting cells. Recent studies in vertebrates suggest that the 
restriction of Numb action to dividing cells reflects its need for 
the protein ACBD3, a partner that is trapped in the Golgi (Zhou 
et al., 2007). Strikingly, physical separation between Numb (a 
cytosolic protein) and ACBD3 (a Golgi protein) prevents Numb 
from affecting Notch in resting cells. During mitosis, however, 
Golgi fragmentation allows ACBD3/Numb complexes to form, 
thereby activating Numb to antagonize Notch activity via an 
unknown mechanism that is independent of Numb concen-
tration (W. Zhong, personal communication) and thus may be 
catalytic. Notably, although mechanistic details of the Numb 
inhibitory mechanism remain to be discovered, this mecha-
nism can be activated in all cells by the expression of a myris-
toylated form of ACBD3 that can constitutively associate with 
Numb. The Numb/ACBD3 complex inhibits lateral signaling 
even in cases where Notch activation results from contact 
between unrelated cells (Zhou et al., 2007). Thus, the coupling 
of ACBD3 retention in the Golgi with asymmetric segregation 
of Numb to one daughter cell is a unique way to take advan-
tage of Golgi fragmentation during mitosis to ensure that Notch 
activity is regulated in a precise spatial pattern (Zhou et al., 
2007). As with Neuralized and Bearded, Notch can feed back 
and regulate Numb levels (Chapman et al., 2006), sustaining 
the signal in cells that attained high levels of Notch activation.
Receptor Glycosylation
Notch receptors are large glycoproteins: many of their EGF 
repeats can be modified by two forms of O-glycosylation, 
O-fucose and O-glucose (reviewed in Haines and Irvine, 
2003; Rampal et al., 2007; Stanley, 2007; Vodovar and Sch-
weisguth, 2008). After translation, the Notch protein is fuco-
sylated on EGF repeats containing the consensus sequence 
C2XXX(A/G/S)(S/T)C3 (C, cysteine; X, any amino acid; A, ala-
nine; G, glycine; S, serine; T, threonine) by the GDP fucose 
protein O-fucosyltransferase (O-fut1 in Drosophila; Pofut1 in 
mammals). Although this modification was initially thought to 
be essential to produce a functional receptor, later studies in 
Drosophila demonstrated that the requirement was actually 
for Ofut’s fucosylation-independent ER chaperone activity. 
Indeed, nonfucosylated Notch receptors are able to reach the cell surface, bind to ligands, and transduce signals (Okajima 
et al., 2008; Rampal et al., 2007; Stanley, 2007; Vodovar and 
Schweisguth, 2008).
Although it is still possible that O-fucosylation can facilitate 
proper Notch folding in the ER, fucosylation does appear to be 
essential for Notch signaling events that require regulation by 
Fringe glycosyltransferases. Fringe proteins extend O-fucose 
by adding more sugar moieties. This modification in the Notch 
ligand binding domain can determine which ligands can bind 
to activate the receptor. Fringe-mediated addition of a single 
N-acetylglucosamine on EGF repeat 12 in Drosophila Notch 
is sufficient to enhance receptor binding to Delta but reduce 
receptor binding to Serrate in vivo and in vitro (Xu et al., 2007). 
Although glycosyltransferase enzymes have been conserved 
between flies and mice, the consequences of Notch glyco-
sylation and fucosylation in flies are not always mirrored in 
mammals (a role for Notch glycosylation has yet to be deter-
mined in C. elegans). Elimination of the fucosylation site on 
EGF repeat 12 of fly Notch led to a hyperactive response to 
Serrate (Jagged) even in the presence of Fringe, but did not 
affect the response to Delta (Lei et al., 2003). However, a sub-
stitution in an analogous position on EGF repeat 12 of mouse 
Notch1 (Threonine 466) generated a hypomorphic allele unable 
to support T cell differentiation (a Delta-dependent process) in 
homozygous animals. When in combination with a null allele, 
it is embryonic lethal (Ge and Stanley, 2008). Mammalian cells 
(Stahl et al., 2008) or animals (Ge and Stanley, 2008; Zhou et 
al., 2008) defective in fucosylation display a profound reduction 
in Notch signaling that extends beyond fringe-dependent pro-
cesses. In contrast to Drosophila, surface Notch3 levels were 
not reduced in mouse Pofut1−/− embryonic stem cells relative 
to wild-type controls (Stahl et al., 2008). Binding of monoclo-
nal antibodies suggested that proper folding of the receptors 
occurred. However, ligand binding was completely abolished, 
consistent with a subtle change in receptor folding (Stahl et 
al., 2008). Indeed, ligand binding in Pofut1-deficient cells can 
be rescued by overexpressing an inactive, unrelated protein 
(α-glycosydase I). Overexpression of α-glycosydase I seems 
to activate structurally unrelated chaperones that refold the 
Notch ECD and rescue ligand binding in Pofut1−/− cells (Stahl 
et al., 2008). This observation supports the general model that 
fucose is not required for ligand binding and suggests that it is a 
global upregulation in chaperone activity and not the dedicated 
chaperone activity of Ofut/Pofut1 that rescues Notch folding 
in mammals. Further support for ligand binding to “sugarless” 
Notch is provided by in vitro binding studies with unmodified 
receptor and ligand-interacting domains expressed and puri-
fied from bacteria (Cordle et al., 2008a; Cordle et al., 2008b).
In mammals, elucidation of the effects of Fringe on Notch 
activity is complicated by the presence of multiple receptors, 
ligands, and Fringe proteins (Lfng, Lunatic fringe; Mfng, Manic 
fringe; and Rfng, Radical fringe). Moreover, vertebrate glyco-
syltransferases appear to make a mechanistic contribution to 
Notch biology that is different from that in flies. Lfng modifies 
Notch in T cells in a manner that enhances Delta-to-Notch sig-
naling and limits Jagged-to-Notch signaling (Visan et al., 2006). 
In contrast, Lfng inhibits Delta-to-Notch signaling in the somite 
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retains its ability to respond to Jagged1, whereas fringe-mod-
ified Notch1 does not (Hicks et al., 2000). The distribution of 
consensus fucosylation and glycosylation sites on mouse 
Notch1 and Notch2 reveals a glycosylation pattern that is 
largely conserved between the two paralogs (Figure 2A). How-
ever, distinct paralog-specific distribution of glycosylation sites 
is apparent within the ligand-binding domain, which may con-
tribute to some of the observed receptor-specific responses 
to ligands (Hicks et al., 2000). Further modifications of Notch 
receptors by β1,4-galactosyltransferases (and possibly sialyl-
transferases) may also play a modulatory role in mammalian 
receptor function in certain contexts (Chen et al., 2001).
The glycosyltransferase RUMI, recently identified in Droso-
phila, is an enzyme that adds O-glucose to serine residues in 
the Notch consensus sequence C1XSXPC2 (Acar et al., 2008). 
Loss of Rumi leads to impaired Notch signaling in a variety 
of contexts, indicating that it is a general regulator of Notch 
signaling. Unlike Ofut1, Rumi’s function resides mainly in its 
glucosyltransferase activity. Notably, Rumi’s contributions to 
Notch signaling are temperature sensitive (even flies lacking 
the gene encoding Rumi are normal at lower temperatures). 
Consistent with this observation, Notch receptors still reach 
the cell surface and bind to ligands in Rumi-deficient cells. 
Although it cannot be ruled out that Rumi regulates subtle 
aspects of Notch receptor folding, stability, or proper mat-
uration, it is possible that O-glucosylation also contributes 
to the receptor activation process. Notably, O-glucose can 
be further extended by additional modifications (possibly by 
xylosyltransferases), but the importance of such modifica-
tions to Notch biology remains to be demonstrated. Delta and 
Serrate/Jagged ligands also contain consensus glycosyla-
tion sites and can be substrates for both O-fucosylation and 
Fringe modification. As Ofut1 and Rumi both appear to func-
tion cell autonomously in signal-receiving cells, the biologi-
cal function of glycosylation in the Notch pathway is largely 
centered on receptor modulation (Haines and Irvine, 2003; 
Stanley, 2007).
The generation of glycosylation-deficient Notch alleles in ver-
tebrates, coupled with the development of improved methods 
to detect the glycosylation status of receptors in various in vivo 
contexts, will undoubtedly continue to make important contri-
butions to the understanding of Notch signaling. However, the 
exact mechanistic contribution of sugars to Notch signaling 
remains a mystery. Glycans appear to play a minor part in the 
ligand/receptor recognition mechanism (Cordle et al., 2008a; 
Cordle et al., 2008b). They may also contribute to the mature 
conformation of the Notch extracellular domain, thereby mod-
ulating the receptor activation process. Although a full molecu-
lar explanation for the differential effects of glycosylation may 
have to wait for the crystal structure of the respective receptor/
ligand complexes, the data we summarized above are consis-
tent with the hypothesis that fucosylation and glycosylation at 
critical residues define the strength of receptor-ligand interac-
tions, altering the probability of activation and consequently 
modulating signal strength. Mammalian and fly Notch proteins 
lacking serine in their 12th EGF repeat may behave differently 
due to variations in the distribution of fucose and glucose on 
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The key to Notch receptor activation is the regulation of ect-
odomain shedding. A crucial regulatory point in Notch signal 
transduction is ligand-induced and ADAM metalloprotease-
mediated Notch receptor cleavage to release the ectodomain 
(Brou et al., 2000; Mumm et al., 2000). The cleavage site S2 
for metalloproteases resides within the negative regulatory 
region of Notch, which encompasses the Lin12-Notch repeat 
(LNR) modules and the heterodimerization domain. The nega-
tive regulatory region functions to prevent Notch proteolysis in 
the absence of ligand. “Leaky” Notch signaling occurs when 
point mutations (Weng et al., 2004) or viral integration (Girard 
et al., 1996) disrupt the negative regulatory region, causing T 
cell acute lymphoblastic leukemia in humans and lymphomas 
in mice, respectively. Mutations in the linker between the LNR 
domains also result in activated Notch phenotypes in C. ele-
gans (Greenwald and Seydoux, 1990), further underscoring the 
conserved nature of the mechanism that keeps Notch “off” in 
the absence of ligands.
How does the negative regulatory region protect the recep-
tor from cleavage by ADAM metalloproteases, and how can 
the Notch ligand reverse this block? Early models attempting 
to explain the function of the negative regulatory region pos-
tulated that receptor oligomers were resistant to proteolysis 
and that ligand binding generated monomeric Notch mole-
cules sensitive to protease cleavage (Kopan et al., 1996; Struhl 
and Adachi, 2000). However, biochemical measurement of the 
oligomeric state of wild-type and mutation-activated Notch 
proteins at the cell surface revealed that the oligomerization 
status of Notch did not correlate with its activity (Vooijs et al., 
2004). Importantly, Notch dimerization was mediated by the 
EGF repeats and not by the negative regulatory region, leav-
ing the negative regulatory region function unexplained (Vooijs 
et al., 2004). Although it is unlikely that oligomerization plays 
a major role in negative regulatory region function, changes 
in oligomerization status may still be important for optimal 
ligand-receptor binding, the stoichiometry of which remains 
to be determined. Ligand and receptor oligomerization plays 
an important role in several other signaling pathways (such as 
signaling pathways mediated by G protein-coupled receptors, 
receptor tyrosine kinases, or integrins), and it will be interesting 
to see whether this will also apply to Notch. Hints that oligomer-
ization could be involved emerge from the ability of receptors 
and ligands to form homodimers via their EGF repeats (Vooijs 
et al., 2004), the clustering of cell surface Notch receptors at 
sites of contact with Delta-expressing cells (Luty et al., 2007; 
Nichols et al., 2007a), and the requirement for soluble (i.e., non-
membrane associated) DSL ligands to be preclustered before 
they can activate Notch receptors on the cell surface (Hicks et 
al., 2002; Varnum-Finney et al., 2000). Receptor and ligand oli-
gomerization may enhance receptor-ligand binding affinity and 
could explain the strong adhesion forces between Delta- and 
Notch-expressing cells as determined by atomic force micros-
copy (Ahimou et al., 2004).
An alternative mechanism for Notch activation was inspired 
by the observation that in Drosophila, the Notch ectodomain is 
trans-endocytosed by ligand-presenting/signal-sending cells, 
whereas the Notch intracellular domain is localized to signal-
receiving cells (Parks et al., 2000) (Figure 1). A genetic link 
between endocytosis and Notch signaling was strengthened 
by the characterization of the dynamin homolog in Drosophila, 
shibire (shi). Dynamin, a pleckstrin homology repeat contain-
ing GTPase, is necessary for pinching off clathrin coated 
pits from the plasma membrane for vesicle formation during 
endocytosis. shi mutants show strikingly similar phenotypes 
to Notch loss-of-function alleles during several developmen-
tal processes in Drosophila. Genetic analyses during periph-
eral nervous system development indicated that NEXT-like 
molecules lacking the negative regulatory region are properly 
processed at site 3 in shi mutants (Struhl and Adachi, 2000), 
demonstrating that endocytosis is only required for negative 
regulatory region-containing molecules. It was proposed that 
the mechanical strain generated by receptor trans-endocyto-
sis somehow exposes site 2 in Notch for protease cleavage 
(Parks et al., 2000). Although this mechanotransduction model 
of Notch activation cannot explain how site 2 cleavage can be 
blocked by the negative regulatory region, it does propose a 
mechanism for how the inhibitory effects of the negative regu-
latory region on site 2 cleavage can be nullified.
Seeing Is Believing: Structural Insights
A recent high-resolution structure of the negative regulatory 
region has provided molecular details regarding its function 
(Gordon et al., 2007). The heterodimerization domain (consist-
ing of HD-N and HD-C) forms a globular folded domain that 
makes extensive contacts with the three calcium-binding LNR 
modules (LNR-A, -B, and -C) (Figure 3A, lower panel). Site 1 is 
located within an unstructured loop that does not contribute to 
the stability of the heterodimerization domain (Gordon et al., 
2008b; Gordon et al., 2007; Malecki et al., 2006). Conversely, 
site 2 is located in a β strand buried within an inaccessible 
pocket in the receptor (Figure 3A, lower panel). Direct steric 
occlusion (by the LNR-AB linker) and global domain stabiliza-
tion (by interactions between LNR-B and the HD-C helix) both 
prevent premature cleavage of the receptor in the absence of 
ligands. Indeed, to produce a Notch receptor with constitutive 
signaling activity, LNR-A, the LNR-AB linker region, and LNR-B 
must all be removed.
The structure of the negative regulatory region clearly 
defines the “off” state of the receptor, confirms that autoinhibi-
tion is intrinsic to monomeric Notch molecules, and physically 
delineates the domain genetically defined to keep the recep-
tor inactive. The structure also provides the molecular logic for 
the requirement of a large-scale conformational movement to 
expose the metalloprotease cleavage site (site 2), a prerequi-
site for Notch activation. However, precisely how this confor-
mational change in the negative regulatory region occurs is still 
controversial. As discussed above, many studies suggest that 
a mechanical force is involved in Notch activation (the mecha-
notransduction model). Given the deep active site pocket in 
the metalloprotease ADAM17/TACE, it has been suggested 
that not only does the receptor activation mechanism forcibly 
lift at least two of the three LNR repeats, but that the process 
must also disengage the stabilizing helix within the heterodi-
merization domain from the site 2 containing strand, perhaps 
by partially unfolding the helix (Gordon et al., 2007). This would 
then allow the metalloprotease access to the scissile bond at site 2 (a model dubbed “lift and cut”) (Gordon et al., 2007). 
Alternatively, because Notch molecules engaged by ligands 
have already been cleaved at site 1 by a protein convertase, 
the mechanical force generated by trans-endocytosis could 
simply be facilitating NECD/NTMIC heterodimer dissociation 
followed by exposure of site 2 for cleavage (Nichols et al., 
2007a). Notably, Drosophila Notch proteins cannot be cleaved 
by protein convertases (Kidd and Lieber, 2002), and yet they 
are still activated by cell-bound ligands and inhibited by solu-
ble ligands lacking the ability to “lift.” Thus, nonenzymatic dis-
sociation may not be a critical intermediate step required for 
the activation of all Notch receptors.
It is also possible that ligand binding leads to an allosteric 
change in the negative regulatory region structure from a pro-
tease-resistant to a protease-sensitive conformation (the allos-
teric model). Allostery does not require force and is more likely 
to occur in receptors with shorter extracellular domains, such 
as the C. elegans Notch receptors Lin-12 and Glp-1. Indeed, 
the allosteric model could provide a possible explanation for 
the ability of soluble DSL ligands to activate Notch in C. ele-
gans but inhibit Notch in flies and vertebrates (but see discus-
sion on DOS coligands below). In this light, it is interesting to 
note that unlike in flies and vertebrates, in C. elegans Notch 
glycosyltransferases are not known to play an important role in 
receptor activation. This is consistent with the notion that gly-
cans can participate in mechanotransduction-mediated recep-
tor activation, (perhaps by contributing to optimal adhesion 
between glycosylated receptors and their ligands), a mecha-
nism that worms would not need if they activate their Notch 
receptor via an allosteric mechanism. According to this view, 
Rumi and Fringe, which do not affect binding (Acar et al., 2008; 
Hicks et al., 2000), could modify the separation forces involved 
in resolving ligand-receptor complexes and/or in the transmis-
sion of such forces to trigger unfolding of the negative regula-
tory region, a prerequisite for site 2 cleavage and subsequent 
receptor activation. It remains to be determined whether differ-
ential glycosylation regulates the adhesion strength between 
Notch and its ligands. Crystallization of ligand/receptor com-
plexes and measurement of the force within individual units 
of receptor-ligand interactions in living cells will help address 
these questions. Additional studies are required to distinguish 
which activation mechanism is occurring in various in vivo con-
texts.
Further support for the importance of the negative regula-
tory region in regulating site 2 accessibility was recently pro-
vided by a consortium effort to develop functional agonistic 
and antagonistic antibodies against Notch3 (Li et al., 2008). 
Two high-affinity antagonists and one agonist were identified 
by the study and found to bind to adjacent epitopes within the 
Notch3 negative regulatory region (Li et al., 2008). The agonist 
increased site 2 cleavage and ectodomain shedding in a recep-
tor-specific and metalloprotease-sensitive manner, whereas 
the antagonists blocked site 2 cleavage in response to ligands. 
Interestingly, the antagonists formed a “lock” by binding to an 
epitope comprising amino acids in both the LNR-A and HD-C 
regions of Notch3, likely increasing the energy required to 
expose site 2. In contrast, the agonist bound to an epitope in 
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between the LNR-A region and the heterodimerization domain. 
That the binding of an antibody to LNR-A can result in increased 
site 2 cleavage and Notch activation suggests that the negative 
regulatory region structure is dynamic, alternating between a 
“closed” (as observed in the crystal structure) and a hypotheti-
cal “open” state. This dynamic structure could potentially even 
allow proteases access to site 2 without ligand binding at some 
low probability, which would provide a possible explanation for 
the recent report of ligand-independent cleavage of full-length 
(i.e., negative regulatory region-containing) Notch receptors by 
ADAM metalloproteases (Delwig and Rand, 2008).
Collectively, these results are consistent with the view that 
limiting accessibility to site 2 is the key function of the negative 
regulatory region. They also support the notion that mechani-
cal force is likely involved in receptor activation and that acti-
vating or cancer-causing mutations in the negative regulatory 
region shift the equilibrium to an “open” state. Similarly, ago-
nistic antibodies and high concentrations of ADAM metallopro-
teases may be trapping or exploiting the “open” conformation 
to activate Notch in a ligand-independent manner. Turning 
Notch signaling “off” pharmacologically via γ-secretase inhibi-
tion has become a common experimental tool. Now, a deeper 
understanding of the site 2 control switch makes it possible 
to transiently turn endogenous Notch signaling “on” whenever 
needed for therapeutic or tissue-engineering purposes. The 
agonistic antibody can thus be viewed as the first truly solu-
ble Notch ligand that binds to the negative regulatory region 
instead of the EGF repeats.
Diffusible Ligands: May the Force be with You
Multiple lines of evidence support the idea that force-generat-
ing mechanical leverage is important in ligand-mediated acti-
vation of Notch and that soluble (and thus diffusible) ligands 
can act as dominant negative proteins to block Notch signaling 
(D’Souza et al., 2008). However, this view of Notch activation 
has been predominantly challenged by the fact that five of the 
ten C. elegans DSL ligands are soluble (Chen and Greenwald, 
2004; Komatsu et al., 2008). If the Notch activation mechanism 
is conserved and requires in all species the unfolding and dis-
sociation of the negative regulatory region, how can diffusible 
DSL ligands like DSL1 in C. elegans activate Notch? One possi-
ble explanation discussed above is that perhaps shorter Notch 
receptors, such as those in C. elegans, allow site 2 exposure to 
proteases by allostery instead of requiring force. However, the 
recent discovery and characterization of five C. elegans coli-
gands suggest an alternative possibility that may move us closer 
to solving this mystery (Komatsu et al., 2008). The authors of 
this recent study noticed that all C. elegans DSL ligands lacked 
the DOS domain that is present in most DSL ligands from other 
phyla (Figure 2B). Remarkably, genetic evidence suggests that 
in C. elegans, DSL ligands lacking the DOS domain cooper-
ate with the soluble DOS domain-containing protein OSM-11 
(and possibly with other DOS proteins) to stimulate Notch acti-
vation in a subset of developmental contexts (Komatsu et al., 
2008). These observations have led to a model proposing that 
secreted and membrane-bound DOS proteins work with mem-
brane-bound and secreted DSL ligands, respectively, to gain 
sufficient mechanical leverage for receptor activation. This 
bipartite ligand binding remains to be confirmed biochemically. 224 Cell 137, April 17, 2009 ©2009 Elsevier Inc.However, the importance of the DOS domain for receptor bind-
ing is supported by positive interactions between LIN-12 and 
OSM-11 in yeast two-hybrid assays (Komatsu et al., 2008) and 
by previous biochemical studies showing that the first two EGF 
repeats of Jagged1 containing the DOS domain were critical for 
high-affinity binding to cell surface Notch receptors (Shimizu et 
al., 1999). Interestingly, DOS domain-only proteins—Delta-like1 
(DLK1) and DLK2/EGFL9—are also found in mammalian cells. 
Mammalian DLK1, when expressed in worms, can compensate 
for the loss of OSM-11 (Komatsu et al., 2008), raising the possi-
bility that DLK1 and possibly DLK2 may have similar functions 
in mammalian cells. It is possible that the two proteins also 
enhance Notch activation by mammalian DSL ligands lack-
ing DOS domains (Dll3, Dll4) in certain physiological contexts 
and compete with DOS domain-containing DSL ligands (Dll1, 
Jag1, and Jag2) in other contexts. It should be noted that Dll3 is 
unable to replace Dll1 in vivo (Geffers et al., 2007) and is unable 
to activate Notch in cultured cells (Ladi et al., 2005). However, 
these experiments in cultured cells may need to be repeated in 
the presence of DLK1 or DLK2 to decisively rule out Dll3 as a 
Notch activator. An additional possibility for the mode of action 
of the secreted DOS proteins and noncanonical ligands is that 
they may interact with extracellular matrix proteins to provide 
sufficient leverage to unfold/dissociate the negative regulatory 
region and activate Notch.
Further support for the importance of the DOS domain stems 
from the crystal structure of human Jagged1 (the first crystal 
structure of a mammalian Notch ligand fragment) (Cordle et al., 
2008a) and from mapping known human and mouse mutations 
in Jagged1 onto the crystal structure (Figure 3B). The crystal-
lized Jagged1 fragment, which contained the DSL domain and 
the first three EGF repeats, has an extended rod-like structure. 
The DSL domain has a distinct organization that bears some 
structural similarities to an EGF repeat (Figure 3B). A positively 
charged cluster of highly conserved residues within the DSL 
domain constitutes a Notch-binding surface, the importance of 
which was confirmed by mutagenesis, in vitro binding assays, 
and in vivo functional assays (Figure 3B) (Cordle et al., 2008a). 
The DOS domain encompasses EGF repeats 1 and 2, which 
exhibit atypical secondary structures but still form the classical 
EGF disulfide bond pattern, therefore defining a distinct func-
tional domain. This domain is structurally similar to a variant 
EGF-like repeat from the stalk region of integrin β2 (Beglova et 
al., 2002). Mutations linked in humans to the genetic disorder 
Alagille syndrome and the congenital heart disorder Tetralogy 
of Fallot and in mice to the autosomal dominant inner ear mal-
formations headturner, (Kiernan et al., 2001), slalom (Tsai et al., 
2001), and Nodder (Ingenium Corporation; personal commu-
nication) cluster near a conserved region in the DOS domain 
(Figure 3B). Together, these amino acids define another poten-
tial receptor-binding surface that is contiguous with the one 
identified in the DSL domain. Mutations in headturner mice 
and human patients of Tetralogy of Fallot affected amino acids 
buried under a protein surface defined by the location of sla-
lom and nodder mutations and may impact the structure of the 
putative Notch binding site within the DOS domain (Figure 3B). 
Although many independent observations confirm that the 12th 
EGF repeat in Notch is critical for ligand binding, the interaction 
domains within Jagged1 span an area greater than EGF repeat 
12 alone (Figures 3A and 3B, all domains at the same scale). 
Elucidation of how the DOS and DSL domains simultaneously 
engage the Notch receptor requires the crystallization of the 
relevant ligand domains (DSL, DOS, and EGF) with the appro-
priate interacting domain from the Notch receptor. Moreover, 
as the sites for modification by the glycosyltransferase Rumi 
and the O-fucosyltransferase Pofut1 are present in repeat 12 
(Figure 3A), it will be interesting to see how sugar moieties 
affect ligand binding.
Together, these recent studies further emphasize the impor-
tance of mechanical leverage in vertebrate Notch activation. 
Therefore, significant concerns arise regarding the interpre-
tation and physiological relevance of observations based on 
Notch activation mediated solely by diffusible ligand frag-
ments, by synthetic DSL peptides, or by bacterially produced 
DSL ligands. Additional studies using ligand molecules that 
harbor mutations in the Notch-binding DOS and DSL motifs, 
as defined by the studies summarized above, are needed to 
establish whether these nonphysiological ligands are truly 
exerting their apparent biological effects via the Notch path-
way.
NEXT Up, Intramembrane Notch Proteolysis
Even though all membrane-tethered forms of Notch can interact 
with γ-secretase within the secretory pathway, only molecules 
with a free N terminus become substrates for intramembrane 
proteolysis by γ-secretase (Shah et al., 2005). The length of this 
extracellular N terminus determines how efficient γ-secretase 
cleavage is; longer regions are less efficiently cleaved. This 
explains why inhibition of metalloproteases, despite dissocia-
tion of the NECD-NTMIC heterodimer at S1 after ligand binding, 
still results in a marked reduction in Notch cleavage at site 3 by 
γ-secretase and thus target activation (Nichols et al., 2007a). 
This is likely also the explanation for why NEXT (Notch extra-
cellular truncation) molecules, the substrates of γ-secretases, 
show decreased cleavage if they are elongated by the fusion 
of an extracellular dimerization domain (Mumm et al., 2000; 
Struhl and Adachi, 2000).
Once NEXT enters the active site of γ-secretase, its trans-
membrane domain is sequentially cleaved starting near the 
cytosolic plasma membrane leaflet (Qi-Takahara et al., 2005; 
Zhao et al., 2005). This initial cleavage at site 3 releases NICD, 
whereas the last cleavage at site 4 releases the Nß peptide 
(named after the Aß peptide, which is released from another 
γ-secretase substrate, amyloid precursor protein, which is 
associated with Alzheimer’s disease; Okochi et al., 2002) (Fig-
ures 1 and 2A). Immunoprecipitation and Edman sequenc-
ing of mouse Notch1 C-terminal fragments identified a single 
NICD species starting at valine 1744 (V1744) (Schroeter et al., 
1998). More recently, mass spectrometric analysis of cleavage 
products from an in vitro assay using NEXT-like substrates 
identified NICD variants with diverse N termini (NICD-V start-
ing with V1744; NICD-L molecules starting with lysine 1745 or 
1746; NICD-S starting with serine 1747) (Figure 2A) (Tagami et 
al., 2008). Quantification of the variants in a reconstituted sys-
tem and in cells treated with proteasome inhibitors showed 
that the predominant scissile bond lies between lysine 1746 
(L1746) and serine 1747 (S1747), and not between glycine 1745 (G1745) and V1744 as previously thought. Importantly, these 
NICD variants were also produced from full-length Notch acti-
vated in cocultures of receptor-producing cells and ligand-
expressing cells, as well as in embryonic and adult mouse 
tissues. Thus, it is highly likely that these variants occur in 
vivo. As expected from the N-end rule in protein degrada-
tion, NICD-S and NICD-L are rapidly degraded by the 26S 
proteasome, making them extremely short-lived in cultured 
cells (Blat et al., 2002; Tagami et al., 2008; Varshavsky, 1996). 
Although we cannot rule out a biological role for these short-
lived products, NICD-V likely mediates the bulk of Notch1 sig-
nals because of its stability. The genetic evidence supporting 
this conclusion comes from reanalysis of mice homozygous 
for the Notch V1744G allele (Huppert et al., 2000), which were 
originally thought to express receptors that are highly resis-
tant to γ-secretase cleavage. Instead, this amino acid sub-
stitution from valine to glycine shifted the γ-secretase cleav-
age site to generate more of the labile NICD-L (Tagami et al., 
2008). The subsequent reduction in NICD stability proves 
detrimental to Notch signaling in vivo (Huppert et al., 2000), 
providing evidence that the labile NICD molecules are insuf-
ficient to compensate for the loss of NICD-V.
Location, Location, Location
In addition to regulating receptor maturation and cell surface 
levels, endosomal sorting has an important role in preventing 
improper ligand-independent Notch receptor activation. Muta-
tions in ESCRT complex proteins vps25 or erupted/Tsg101/
vps23 lead to accumulation of Notch in late endosomal ves-
icles that permit ectopic activation of Notch via γ-secretase-
dependent proteolysis (Vaccari et al., 2008). Because Notch 
ligand also accumulates in these vesicles, it is unclear whether 
the ectopic activation process is due to receptor stimulation by 
ligands in cis or an ectodomain shedding-independent activity 
of γ-secretase. Another protein, Lethal (2) Giant Discs (LGD) 
is also required to maintain Notch in an “off” state. When the 
levels of LGD protein are altered by either gene loss or over-
expression, ligand-independent Notch activation is observed 
(Nichols et al., 2007b). It remains to be seen whether ADAM 
metalloproteases and γ-secretase are involved in this ligand-
independent receptor activation. Notably, loss of hrs, an FYVE 
finger domain-containing endocytic protein, leads to Notch 
accumulation in an early endosomal compartment upstream 
of the ESCRT or LGD proteins but does not lead to ectopic 
activation. Therefore, the ESCRT complexes and LGD are likely 
to be normally involved in Notch downregulation, indicating 
that endosomal sorting acts to restrict receptor activation at 
or near the cell surface. Mistrafficking of Notch may place it in 
a compartment where proteolysis is less constrained, perhaps 
because the negative regulatory region shifts to an “open” 
conformation at a lower pH. Thus, defects in endosomal sort-
ing of Notch may contribute to pathogenesis in different cel-
lular contexts.
The identification of the subcellular location where cleav-
age of Notch at site 3 and site 4 occurs during the normal 
ligand-activation process has been controversial. Dynamin/
shi, Rab5, and the endocytic syntaxin avl, which are all 
involved in early endosome formation, are required in sig-
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endocytosis is not required for NEXT cleavage in vivo (Struhl 
and Adachi, 2000), it was suggested that monoubiquitination 
and endocytosis of Notch are required to target the Notch/γ-
secretase complex into an endocytic vesicle where efficient 
site 3 cleavage occurs. Indeed, the substitution of lysine 1749 
with arginine (K1749R) in Notch simultaneously abolished 
monoubiquitination, endocytosis, and NICD accumulation 
(Gupta-Rossi et al., 2004). However, an alternative expla-
nation for this result emerged from analysis of the K1749R 
transmembrane domain mutant for scissile bond selection by 
γ-secretase. Like V1744G, the K1749R substitution caused a 
shift in scissile bond preference, producing labile NICD spe-
cies instead of NICD-V and thus leading to a loss of Notch 
activity. In addition to transmembrane domain composition, 
scissile bond selection was also strongly influenced by the 
subcellular localization of the γ-secretase/substrate com-
plex during cleavage (Figure 1) (Tagami et al., 2008). At the 
plasma membrane, the bond between G1743 and V1744 is 
preferentially cleaved to generate the stable NICD-V species. 
However, in endosomes, γ-secretase preferentially cleaves 
the bond between L1746 and S1747, generating labile NICD-L 
and NICD-S species. This change in bond preference may 
be due to a lower pH in endosomes or due to differences in 
lipid environments, which may not only impact the specific 
activity of γ-secretase (Osenkowski et al., 2008) but also alter 
the positioning of the substrate transmembrane domain and 
thus cleavage site selection. The notion that stable NICD-V 
is generated at the plasma membrane or in the earliest ves-
icles to pinch off from the plasma membrane is consistent 
with the observation that non-cell-permeable γ-secretase 
inhibitors can still block Notch proteolysis (Tarassishin et al., 
2004). Therefore, although γ-secretase is active in many cel-
lular membranes and its proteolytic activity is independent of 
the composition of the Notch transmembrane domain, scis-
sile bond selection and, consequently, the stability of NICD 
are highly dependent on both receptor cellular location and 
transmembrane domain composition (Tagami et al., 2008). It 
is clear that future efforts to correlate Notch activity, endo-
somal location, and proteolysis will have to take NICD species 
and half-life into consideration in order to properly assess the 
presence or absence of NICD/Notch activity. It is worth not-
ing in this context that the apical polarity protein Crumbs was 
proposed to restrict the activity of γ-secretase and thus to 
limit the extent of Notch activation (Herranz et al., 2006). This 
too needs to be reevaluated as Crumbs may instead impact 
scissile bond selection by γ-secretase.
So what is the role of endocytosis in Notch activation? The 
important observation that NICD-V is produced before or 
during budding of the endocytic vesicle led us to revisit the 
hypothesis that translocation into a “cleavage endosome” is 
an important step in Notch activation. An alternative explana-
tion for the phenotypes associated with the loss of dynamin/
shi, Rab5, or syntaxin avl in signal-receiving cells (Vaccari et 
al., 2008) is that these protein deficiencies lower the forces 
generated by trans-endocytosis of ligand, thereby reducing 
ligand-induced negative regulatory region dissociation and 
subsequent receptor activation. If this interpretation is cor-
rect, the expression of receptors containing point mutations 226 Cell 137, April 17, 2009 ©2009 Elsevier Inc.in the negative regulatory region that affect domain folding 
but remain ligand-dependent should suppress Rab5, shi, or 
avl mutations.
Interestingly, it was recently reported that the loss of the 
aquaporin-related channel Big Brain (bib), one of the earliest 
identified neurogenic genes in Drosophila, impaired endosomal 
maturation and, consequently, reduced Notch signaling during 
neurogenesis. Loss of bib suppressed ectopic Notch activation 
in ESCRT mutants (Kanwar and Fortini, 2008). Surprisingly, Bib 
exerts its effects on Notch signaling not by preventing Notch 
from entering into a “cleavage endosome” but by acting down-
stream of cleavage at site 3 (Kanwar and Fortini, 2008). Trun-
cated, NEXT-like Notch molecules were cleaved in bib−/− cells to 
form a NICD-like fragment, but ectopic Notch activity was not 
detected, indicating that nuclear entry or target activation was 
impaired (Kanwar and Fortini, 2008). However, the bib−/− phe-
notypes do not indicate a general deficiency in nuclear entry of 
key cytosolic proteins (for example, the transcription activators 
SMAD and Armadillo). The effects of NICD overexpression also 
displayed no requirement for bib, establishing that loss of Bib 
does not compromise the NICD nuclear translocation machin-
ery, CSL availability, or target gene activation. Instead, the gen-
erated NICD appears to remain associated with endosomes. 
Acidification of endosomes fails to occur in bib−/− cells. Indeed, 
Bib proteins that lack ion channel activity mimic bib loss of 
function (Kanwar and Fortini, 2008). How the release of NICD 
could be affected by the acidity of endocytic compartments 
in specific developmental contexts remains to be elucidated. 
It has been proposed that the defect might reflect impaired 
association of the endosome with cytoskeletal or cytoplasmic 
transport factors (Kanwar and Fortini, 2008). An alternative 
explanation for these observations is that in bib−/− cells, scis-
sile bond selection by γ-secretase is altered such that cleavage 
occurred closer to the middle of the transmembrane domain to 
produce NICD molecules with longer, more lipophilic N termini 
that keep NICD anchored to the membrane. As the resolution 
of western blots is not sufficient to compare the composition 
of NICD produced by wild-type and bib−/− cells, testing this 
hypothesis will require mass spectrographic analysis of the 
NICD species produced in bib−/− endosomes.
γ-Secretase, Adding to the Complexity
The cleavage of Notch by γ-secretase was traditionally thought 
of as a constitutive proteolytic event, with the critical regula-
tory steps occurring either upstream (i.e., during ligand binding 
and ectodomain shedding) or downstream (i.e., NICD degrada-
tion, as discussed below) of intramembrane receptor cleavage. 
However, as γ-secretase activity and function have been further 
characterized, we have come to realize that intramembrane 
proteolysis can also be regulated by a variety of factors (Parks 
and Curtis, 2007). γ-Secretase is composed of four membrane 
proteins in a 1:1:1:1 stoichiometry (Sato et al., 2007). These four 
proteins—the catalytic component presenilin and three limit-
ing cofactors, NCT (Nicastrin), Pen2, and Aph1—are necessary 
and sufficient to reconstitute enzymatic activity in cells lacking 
the activity (yeast, Sf9 cells). Because mammals have two pre-
senilin isoforms and at least two APH isoforms (three in mice), 
mammalian cells can have at least four different γ-secretase 
enzyme complexes with differing biochemical properties and 
protein interactions. Indeed, presenilin1-containing complexes 
exhibit specific activities distinct from presenilin2-containing 
complexes; γ-secretases containing different Aph1 isoforms 
also make different contributions in vivo (Tolia and De Strooper, 
2008). Although the relevance of γ-secretase composition to 
Notch biology is still unexplored, some studies suggest that dif-
ferent Aph1 complexes might contribute differentially to Notch 
signaling (Tolia and De Strooper, 2008). Some of the remain-
ing key questions are whether different γ-secretase complexes 
reside in different subcellular locations, whether they have 
different requirements for enzymatic activity (such as optimal 
pH and membrane lipid composition), and, most importantly, 
whether they can provide a biochemical basis for scissile site 
selection in Notch.
Notably, like many type I transmembrane proteins, Notch 
ligands are also subject to extracellular cleavage by ADAM 
proteases followed by transmembrane domain cleavage by 
γ-secretase (D’Souza et al., 2008). Ligand processing may 
be important to prevent any antagonistic effects of the active 
ligand on the ligand-producing cell, to limiting active ligand 
availability, or to promote efficient membrane clearance for 
ligand presentation to Notch-signal receiving cells. Although 
ligand processing could, in principle, generate biologically 
active fragments, no physiological evidence has yet emerged 
to support bidirectional signaling by the ligand intracellular 
domains that result from cleavage events.
Transcriptional Regulation
Once NICD is released by γ-secretase, it translocates into the 
nucleus. The processes and proteins that regulate nuclear 
translocation are still unclear. In the nucleus, NICD is unable to 
bind DNA on its own, but it acts to affect transcription with the 
help of its partner, a CSL protein. CSL directs NICD to specific 
target genes, the recognition of which appears to be indepen-
dent of Notch. NICD/CSL could also affect nuclear events by 
competing with other proteins for the transcription coactivator 
Mastermind (MAM; MAML in mammals). The nuclear milieu that 
exists before the arrival of NICD will dictate which targets are 
available to CSL and thus can be activated by Notch (reviewed 
in Bray, 2006). Recent studies have begun to explore this regu-
lation in greater detail.
CSL as a Repressor
Studies in Drosophila indicate that in the absence of NICD, the 
CSL protein Su(H) actively represses its target promoters. Loss 
of Su(H) in flies also lacking the γ-secretase component prese-
nilin results in transient activation of Notch target genes (Koelzer 
and Klein, 2006). Su(H) mediates transcriptional repression by 
recruiting the transcriptional corepressor proteins SKIP, hair-
less/CtBP, and Gro/TLE (reviewed in Bray, 2006). In addition, 
Su(H) can silence transcription at multiple sites via recruitment 
of Asf1, a histone chaperone involved in nucleosome assembly 
(Goodfellow et al., 2007). Interestingly, modulating Asf1 lev-
els does not impact gene targets of the Wnt, sonic hedgehog 
homolog (SHH), transforming growth factor (TGF), or epidermal 
growth factor (EGF) pathways (Goodfellow et al., 2007), imply-
ing that Asf1 has a specific role in repressing Notch targets. 
In cultured Drosophila S2-N cells, SKIP associates with Su(H) 
in the repressor complex. Importantly, whereas knockdown of Su(H) in S2-N cells derepressed only the two genes regulated 
by Notch, M3 and Mß (Krejci and Bray, 2007), knockdown of 
Asf1 derepressed additional genes within the E(spl) complex, 
a cluster of linked genes encoding bHLH proteins. Curiously, 
Asf1-repressed genes were not randomly distributed but rather 
were all located centromeric to M3 (Goodfellow et al., 2007), 
thus dividing the E(spl) locus in two domains of transcription 
activation and repression. Asf1 must remain associated with 
these promoters to maintain a stable nucleosome complex 
for transcriptional repression in the absence of Su(H), which 
is required for the inititial recruitment of Asf1 to all these sites 
but is only required for Asf1 retention telomeric to M3. By infer-
ence, Su(H)/SKIP/hairless/Asf1 complexes must transiently 
bind to such sites, delivering Asf1 to an unknown partner, 
which helps in its retention in regions centromeric to M3. In the 
mammalian nucleus, although the CSL protein RBPjκ can form 
complexes with many ubiquitous corepressor proteins, such 
as CIR, FLH1C/KyoT2, and NCoR/SMRT (reviewed in Bray, 
2006), it is SHARP/MINT/SPEN that has emerged as the critical 
repressor of Notch target genes in vivo (Oswald et al., 2005; 
Tsuji et al., 2007).
It is important to note that target repression by CSL proteins is 
not the rule. In contrast to the case in Drosophila, the loss of the 
CSL protein LAG-1 in C. elegans does not result in phenotypes 
characteristic of a gain-of-Notch function (but see Ghai and Gau-
det, 2008). In addition, expression of ref-1, a gene target in many 
Notch-mediated decisions, is not elevated when CSL binding sites 
are mutated (Neves et al., 2007). Therefore, in nematodes, Notch 
targets are already poised for transcription and are not actively 
repressed by LAG-1. In mammalian skin, the phenotype of RBPjκ 
loss is not as severe as that seen when multiple Notch recep-
tors or γ-secretase is lost, an observation that could be consistent 
with derepression of Notch targets in RBPjκ null animals (Demehri 
et al., 2008). Surprisingly, removal of RBPjκ in Notch or presenilin 
mutants did not alleviate their phenotype, suggesting that in the 
skin, target repression does not play an important role and raising 
the possibility that Notch signals in that tissue in a poorly defined, 
RBPjκ-independent manner (Demehri et al., 2008). Similarly, tar-
get derepression was not observed during the differentiation of T 
helper cells (Ong et al., 2008).
The lack of derepression is consistent with the recent find-
ings that CSL occupancy of many Notch target promoters in 
Drosophila is transient. In Drosophila cells, silenced regions in 
the promoters of genes encoded within the E(spl) complex are 
rarely occupied by Su(H) (Krejci and Bray, 2007). However, in 
cultured human cells, CSL can be continuously detected at the 
Hes1 promoter in the absence of NICD (Fryer et al., 2004; Krejci 
and Bray, 2007). Notably, in both Drosophila and human cells, 
CSL occupancy on the promoter is always enhanced when 
NICD is present. Taken together, these studies demonstrate 
that CSL occupancy on the target promoters can be a dynamic 
process. Whether different Notch targets distinguished by dif-
ferential CSL occupancy will have different activation kinetics 
is an interesting point for future investigation.
Transcriptional Activation and Target Selection
Whether there is active repression or not, the binding of NICD 
to CSL mediates the “transcriptional switch” to activate gene 
expression from the target promoter. The crystal structures of Cell 137, April 17, 2009 ©2009 Elsevier Inc. 227
Notch, CSL, and the Notch/CSL/MAM nuclear complexes from 
multiple organisms provide details of this transcriptional acti-
vation process at atomic resolution (reviewed in Gordon et al., 
2008a; Kovall, 2008). These structures confirm that the activa-
tion complex forms in a stepwise manner and give insights with 
regard to the molecular changes likely to facilitate switching 
from repression to activation (reviewed in Barrick and Kopan, 
2006; Gordon et al., 2008a; Kovall, 2008). The high-affinity 
binding of the RAM domain to CSL increases the local con-
centration of ANK domains, thereby permitting it to bind to 
RBPjκ and promote dissociation of transcriptional repressors 
(Del Bianco et al., 2008; Friedmann et al., 2008; Lubman et al., 
2007). The ANK/CSL interface is then recognized by the tran-
scriptional coactivator Mastermind/LAG-3 (Nam et al., 2006; 
Petcherski and Kimble, 2000; Wilson and Kovall, 2006). This 
ternary complex recruits histone acetyltansferases, chroma-
tin remodeling factors, and the Mediator complex (Fryer et al., 
2004) to assemble an active transcription complex on target 
promoters. Importantly, the 74 amino acid domain of mam-
malian Mastermind (MAML1), which binds to ANK/RBPjk, is a 
potent, global, and apparently specific inhibitor of Notch sig-
naling (for example, see Maillard et al., 2008).
When Notch target promoters contain optimally spaced 
head-to-head sites [Su(H) paired sites], cooperative binding 
between two CSL/NICD/MAM complexes mediated by ANK/
ANK domain interactions is observed in vitro (Nam et al., 2007). 
Though cooperativity explains why binding site orientation is 
important (Cave et al., 2005; Ong et al., 2006), it is unclear 
whether such cooperatively bound complexes are important in 
vivo and whether they also form on promoters in which spac-
ing is suboptimal. Notably, the amino acids mediating these 
protein interactions are conserved on all four vertebrate Notch 
paralogs, allowing one to speculate that heterotypic interac-
tions between different Notch paralogs may refine the regula-
tion of transcription by Notch proteins (Nam et al., 2007). These 
specific amino acids are not conserved in C. elegans Notch 
proteins, but interestingly, Su(H) paired sites are also not con-
served in the genomes of different nematode species (Neves 
and Priess, 2005). It is important to note that in vertebrates, 
multimerization of CSL binding sites (with head-to-tail orienta-
tion) is sufficient to elicit Notch-dependent activation in vivo in 
some but not all tissues responsive to Notch signaling (Mizu-
tani et al., 2007; Souilhol et al., 2006).
It is tempting to describe Su(H) paired site-containing genes 
as high-affinity Notch targets. However, it is clear that even 
Hes1, the archetypical Su(H) paired site-containing Notch tar-
get, is not always responsive to Notch1 (Lee et al., 2007) and 
that many genes that contain Su(H) paired sites in their promot-
ers do not respond to Notch signaling (Neves and Priess, 2005). 
Moreover, many characterized Notch-responsive enhancers 
are combinatorial. In C. elegans, Notch (LIN-12) cooperates 
with a GATA related protein to regulate ref-1 expression in the 
endoderm, but cooperates with an NK-class factor to drive 
ref-1 expression in the mesoderm (Neves et al., 2007). In Dros-
ophila, Notch cooperates with the bHLH protein daughterless 
(Cave et al., 2005) or the transcription factor grainyhead (Fur-
riols and Bray, 2001) to activate Su(H) paired site-containing 
promoters of the E(spl) complex genes. It is conceivable that 228 Cell 137, April 17, 2009 ©2009 Elsevier Inc.tissue-specific target gene expression is controlled by the abil-
ity of different Notch paralogs to synergize or physically inter-
act with diverse transcription factors bound on neighboring 
enhancers. Evidence for a qualitative difference among Notch 
paralogs was recently shown in vitro, where Notch3 seemed 
best equipped among the paralogs to cooperate with a nearby 
zinc finger protein (Ong et al., 2006).
Additional Partners in the Nucleus?
Several studies have shown that when overexpressed, NICD 
can interact with different transcriptional cofactors from multi-
ple signaling pathways (for example, SMADs, NFκB, and HIF1α) 
to impact transcription from their target promoters (Kluppel 
and Wrana, 2005; Poellinger and Lendahl, 2008). These inter-
actions likely reflect binding of adjacent enhancer-associated 
complexes by transcription activation complexes containing 
NICD. Given what is known about NICD, it is less likely that 
these observations reflect the distribution of NICD molecules 
among new transcription cofactor partners according to bind-
ing affinity and the local concentrations of such partners. As 
mentioned earlier, NICD interacts with CSL through a con-
served WxP motif in its RAM domain with a small contribu-
tion from its ANK domain. Despite some sequence divergence, 
all four mammalian NICD RAM domains interact with the CSL 
protein RBPjκ with a similar affinity of ?200 nM (Del Bianco 
et al., 2008; Friedmann et al., 2008; Lubman et al., 2007). 
Although this affinity is not high enough to exclude the pos-
sibility that NICD associates with other proteins, it is important 
to note that free NICD is not detected at equilibrium in vitro 
when RBPjκ is in stoichiometric excess (Lubman et al., 2007). 
Therefore, under physiological conditions in the nucleus where 
a high concentration of RBPjκ is coupled with a low concen-
tration of NICD, it is unlikely that there will be many free NICD 
molecules available to associate with other partners. However, 
it cannot be ruled out that when the concentration of RBPjκ 
proteins is limiting, some NICD molecules could associate with 
other factors such as SMAD, HIF1α, or NFκB. This remains to 
be demonstrated with physiological concentrations of NICD. 
Notably, RBPjκ can associate with at least one partner other 
than Notch—the bHLH protein p48/PTF1a (Beres et al., 2006; 
Hori et al., 2008; Masui et al., 2007). Thus, perhaps some of the 
effects of NICD overexpression could merely be the result of 
NICD titrating RBPjκ away from other binding partners.
This titration effect by NICD may explain some observations 
made in mammalian cells. As is the case with RBPjκ, MAM 
proteins can also associate with other transcription factors 
such as β-catenin, Mef2c, and p53 (reviewed in McElhinny et 
al., 2008). In mammalian cells, competition between NICD and 
the myogenic factor Mef2c for binding of MAML1 may offer 
a long-sought-after mechanism for the inhibition of myogen-
esis by truncated Notch ANK domains. Even though the NICD 
ANK domain alone cannot activate Notch targets, it could still 
associate with RBPjκ when overexpressed and thus titrate 
MAM away from Mef2C. In summary, it appears that both the 
coactivators and corepressors that act in the Notch signal-
ing pathway are shared with other pathways, thus providing 
an alternative explanation for why overexpression of NICD can 
impact transcription of genes regulated by proteins outside of 
the Notch pathway.
All Good Things Must Pass: Signal Downregulation
Activation of Notch receptors releases a quantum of signal in 
the form of NICD. Given what we know about Notch biology, 
sustained NICD accumulation can be deleterious. Highlighting 
the importance of NICD turnover is the observation that dele-
tion of the Notch receptor C-terminal or PEST domain, or muta-
tions that stabilize NICD, can cause T cell acute lymphoblastic 
leukemia in humans (Weng et al., 2004). Thus, in addition to 
the above-mentioned mechanisms that primarily control NICD 
production, optimal signal strength is regulated in most cells 
by ensuring that NICD half-life is short. Most Notch-mediated 
processes require a transient pulse of activity that in some 
cases lasts only as long as a fraction of the cell cycle (Ambros, 
1999). Even the few processes that require prolonged activa-
tion still seem to modulate activation strength. One such regu-
lation point occurs during the transcriptional activation pro-
cess, wherein NICD is phosphorylated within the PEST domain 
by the CDK8 kinase and targeted for proteasomal degradation 
by E3 ubiquitin ligases that include Sel10/Fbw7 (Fryer et al., 
2004; O’Neil et al., 2007; Thompson et al., 2007; Tsunematsu 
et al., 2004). This process eliminates NICD, disassembles the 
transcription activation ternary complex, and resets the cell 
for the next round of signaling. It remains to be established 
whether CDK8 and Fbw7 are general mediators of NICD degra-
dation. Other kinases and E3 ubiquitin ligases are likely to also 
participate in NICD regulation in context-dependent circum-
stances. Indeed, analysis of T cell acute lymphoblastic leuke-
mia-associated Notch deletion alleles identified a conserved 
regulatory phosphorylation site (WSSSSP) in Notch proteins 
that is disrupted in patients of the disease (Chiang et al., 2006). 
The kinases, phosphatases, and ubiquitin ligases that target 
this site remain to be identified and characterized.
Conclusions and Perspectives
The efforts to understand the role developmental pathways 
play in adult tissue homeostasis and disease requires detailed 
knowledge of how the “on” and “off” states of such pathways 
are brought about and what mechanisms ensure their robust-
ness. This knowledge should reveal vulnerabilities in the path-
ways that lead to disease and should provide insights into how 
to control or restore the balance to achieve a desired biological 
outcome. In the three decades following the cloning of Notch, 
a significant body of work has provided detailed mechanistic 
understanding of Notch activation and signal transduction. 
These efforts have provided new tools with which to inhibit or 
activate Notch signals. They have further allowed for atomic-
level resolution of key structural elements involved in Notch 
receptor activation and transcription complex assembly. We 
now await structural analysis of ligand-receptor complexes 
and direct measurements of forces involved in Notch activa-
tion. These will provide information necessary to bridge the 
major gaps in our understanding of this unique ligand-medi-
ated receptor activation mechanism. Better understanding 
of the growing array of combinatorial possibilities of DOS 
protein-DSL ligand interactions that could enable fine control 
over forces exerted by ligands on Notch (and, hence, activa-
tion probability) will also provide insights into Notch activa-
tion mechanisms. CSL-corepressor complexes also need to be examined at the atomic level to allow for better elucidation 
of the transcriptional switch. Together with ongoing efforts to 
identify and characterize cellular activities that enable other 
signaling pathways to control the output from Notch proteins, 
these areas of inquiry offer the promise of research tools to 
better our understanding of the pleiotropic effects of Notch 
signaling in development and disease as well as additional 
potential therapeutic avenues.
Recent studies have also led to a new appreciation of the 
underlying complexities of Notch proteolytic activation. Scissile 
bond selection, the impact of N-end rule degradation, and the 
dependence of both on the subcellular location of the cleavage 
activity will necessitate redesigning of experiments seeking 
to measure NICD production. Further developments in mass 
spectrometry may one day enable analysis of peptides isolated 
from small biological samples, thereby improving investigation 
into the function of the various endocytic trafficking modula-
tors of Notch. Improvements in chromatin immunoprecipita-
tion (ChIP) technology that will allow for the detection of NICD 
at physiological levels (currently not feasible) will undoubtedly 
uncover new nuclear partners and help to complete the story 
of target selection by different Notch paralogs in different cel-
lular contexts (see Krejci et al., 2009).
Another major hurdle yet to be addressed relates to the issue 
of receptor redundancy. In which processes do Notch paralogs 
have specific or redundant functions and what are the underlying 
molecular mechanisms governing these differences? Do hetero-
typic NICD interactions occur at target promoters, and do they 
have a biological function? Developmental syndromes associ-
ated with Notch loss will benefit from receptor-specific agonists 
or activation of paralog-specific targets, if present. Receptor-
specific antagonists (for example, Notch1 inhibition in T cell 
acute lymphoblastic leukemia) are predicted to work better than 
γ-secretase inhibitors if redundancy with other Notch paralogs 
will alleviate the toxicity associated with general Notch pathway 
inhibition. Related to this issue are mechanistic questions regard-
ing how target selection and activation by different Notch paral-
ogs is achieved, as well as what the functional thresholds attained 
by different concentrations of NICD are. Despite some progress 
in tools for monitoring Notch pathway activity (for example, see 
Ohtsuka et al., 2006; Souilhol et al., 2006; Vooijs et al., 2007), 
the field will benefit greatly from improvements in the methods 
used (for example, cleavage-specific antibodies, reporter strains, 
noninvasive imaging approaches) to identify cells engaged in 
Notch signaling, to quantify the levels of all four NICD proteins, 
to monitor target activation, and to record its biological conse-
quences. Finally, despite genetic confirmation that noncanonical 
γ-secretase-dependent but RBPjk-independent Notch signaling 
occurs in flies and mammals, its mechanism remains as obscure 
as ever, presenting another interesting challenge to the field.
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